These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27058936)

  • 1. Uncertain Oversight of Regenerative Medicines in Japan under the ASRM.
    Lysaght T; Sugii S
    Cell Stem Cell; 2016 Apr; 18(4):438-9. PubMed ID: 27058936
    [No Abstract]   [Full Text] [Related]  

  • 2. Accelerating Cell Therapy for Stroke in Japan: Regulatory Framework and Guidelines on Development of Cell-Based Products.
    Houkin K; Shichinohe H; Abe K; Arato T; Dezawa M; Honmou O; Horie N; Katayama Y; Kudo K; Kuroda S; Matsuyama T; Miyai I; Nagata I; Niizuma K; Sakushima K; Sasaki M; Sato N; Sawanobori K; Suda S; Taguchi A; Tominaga T; Yamamoto H; Yamashita T; Yoshimine T;
    Stroke; 2018 Apr; 49(4):e145-e152. PubMed ID: 29581346
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulatory Frameworks for Gene and Cell Therapies in Japan.
    Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
    Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.
    Takashima K; Morrison M; Minari J
    Stem Cell Reports; 2021 Jun; 16(6):1425-1434. PubMed ID: 34019814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative regenerative medicines in the EU: a better future in evidence?
    Corbett MS; Webster A; Hawkins R; Woolacott N
    BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA should stand firm on stem-cell treatments.
    Nature; 2016 Jul; 535(7610):7-8. PubMed ID: 27383946
    [No Abstract]   [Full Text] [Related]  

  • 7. Stamina therapies: Let the record stand.
    Bianco P; Cattaneo E; De Luca M; Pani L
    Nature; 2014 Feb; 506(7489):434. PubMed ID: 24572414
    [No Abstract]   [Full Text] [Related]  

  • 8. Science-based assessment of source materials for cell-based medicines: report of a stakeholders workshop.
    Stacey G; Andrews P; Asante C; Barbaric I; Barry J; Bisset L; Braybrook J; Buckle R; Chandra A; Coffey P; Crouch S; Driver P; Evans A; Gardner J; Ginty P; Goldring C; Hay DC; Healy L; Hows A; Hutchinson C; Jesson H; Kalber T; Kimber S; Leathers R; Moyle S; Murray T; Neale M; Pan D; Park BK; Rebolledo RE; Rees I; Rivolta MN; Ritchie A; Roos EJ; Saeb-Parsy K; Schröder B; Sebastian S; Thomas A; Thomas RJ; Turner M; Vallier L; Vitillo L; Webster A; Williams D
    Regen Med; 2018 Dec; 13(8):935-944. PubMed ID: 30488776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA's claims over stem cells upheld.
    Cyranoski D
    Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
    [No Abstract]   [Full Text] [Related]  

  • 10. Balancing Safety and Efficacy With Early Availability in the Regulation of Regenerative Medicine Product.
    Fujiwara Y; Maruyama Y; Honda F
    Clin Pharmacol Ther; 2021 May; 109(5):1182-1185. PubMed ID: 32979224
    [No Abstract]   [Full Text] [Related]  

  • 11. Stem cells: taking a stand against pseudoscience.
    Cattaneo E; Corbellini G
    Nature; 2014 Jun; 510(7505):333-5. PubMed ID: 24955466
    [No Abstract]   [Full Text] [Related]  

  • 12. Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products.
    Hourd P; Chandra A; Alvey D; Ginty P; McCall M; Ratcliffe E; Rayment E; Williams DJ
    Regen Med; 2014; 9(6):799-815. PubMed ID: 25431916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory perspectives of Japan.
    Kusakabe T
    Biologicals; 2015 Sep; 43(5):422-4. PubMed ID: 26028474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regenerative medicine legislation in Japan for fast provision of cell therapy products.
    Fujita Y; Kawamoto A
    Clin Pharmacol Ther; 2016 Jan; 99(1):26-9. PubMed ID: 26482927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Translation of Cell Therapy, Tissue Engineering, and Regenerative Medicine Product in Malaysia and Its Regulatory Policy.
    Bt Hj Idrus R; Abas A; Ab Rahim F; Saim AB
    Tissue Eng Part A; 2015 Dec; 21(23-24):2812-6. PubMed ID: 26192075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical biosafety evaluation of cell-based therapies: emerging global paradigms.
    Basu J; Assaf BT; Bertram TA; Rao M
    Toxicol Pathol; 2015 Jan; 43(1):115-25. PubMed ID: 25476796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caution urged in trial of stem cells to treat spinal-cord injury.
    Barde Y
    Nature; 2009 Mar; 458(7234):29. PubMed ID: 19262651
    [No Abstract]   [Full Text] [Related]  

  • 18. Rejuvenating Regenerative Medicine Regulation.
    Charo RA; Sipp D
    N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
    [No Abstract]   [Full Text] [Related]  

  • 19. Preparing regenerative therapies for clinical application: proposals for responsible translation.
    Shapiro SA; Smith CG; Arthurs JR; Master Z
    Regen Med; 2019 Feb; 14(2):77-84. PubMed ID: 30651044
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.